Drug Type Monoclonal antibody |
Synonyms Anti-Ctla-4 Antibody, Anti-CTLA-4 antibody(Agenus), Anti-Ctla-4 Antibody(Agenus, Inc.) + [3] |
Target |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | AM | 01 May 2024 | |
Colorectal Liver Metastases | Phase 2 | US | 26 Mar 2024 | |
Liver metastases | Phase 2 | US | 26 Mar 2024 | |
Adenocarcinoma of large intestine | Phase 2 | US | 11 May 2023 | |
Advanced Colorectal Adenocarcinoma | Phase 2 | US | 11 May 2023 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | US | 11 May 2023 | |
Microsatellite Stable Colorectal Carcinoma | Phase 2 | US | 11 May 2023 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | US | 27 Mar 2023 | |
Secondary malignant neoplasm of pancreas | Phase 2 | US | 27 Mar 2023 | |
Melanoma | Phase 2 | US | 12 Dec 2022 |
NCT03860272 (ASCO2024) Manual | Phase 1 | Microsatellite Stable Colorectal Carcinoma Microsatellite Stable (MSS) | 77 | ingbeibrct(eoiogwuvqv) = ntlhmeeger nvkczurjty (uljgtqtqyl ) View more | Positive | 24 May 2024 | |
Phase 2 | Colorectal Cancer Neoadjuvant Proficient DNA Mismatch Repair (pMMR) | Deficient DNA Mismatch Repair (dMMR) | MSI-High | ... View more | 12 | zdrchzspoq(iazoxhvxhi) = zompraubxi krfjktjfhw (yfqbiaqxyl ) Met View more | Positive | 18 Jan 2024 | ||
NCT03860272 (ESMO2023) Manual | Phase 1 | 22 | ujteeewidv(uijhgyzyiq) = pyxgsbsrnx ttpwouzrnf (kngjlqdmgp ) View more | Positive | 21 Oct 2023 | ||
Phase 1 | Metastatic Microsatellite Stable Colorectal Carcinoma RAS mutations | BRAF mutations | tumor mutational burden (TMB) | 101 | tzeqssfjzn(xlcvyxalny) = sercqlfvtt zaslezdbwc (odkbdwleam, 68 - 88) View more | Positive | 01 Jul 2023 | ||
Phase 1 | 59 | teawbwsiba(ilguawocpq) = hqmdursczj eqgnpavvbb (tncjdiaoio ) View more | Positive | 24 Jan 2023 | |||
(1 mg/kg pts) | rjwcibemqj(htdnsfeunp) = ettrnlwjha fecmrpasjm (oyyggyymdp, 63 - 100) View more | ||||||
Phase 1 | 13 | bersuabisj(zdhbsmgojl) = lvrljmynsz eehqrxlhbl (oaisnsogpn ) View more | Positive | 17 Nov 2022 | |||
Phase 1 | 41 | bxgsxhkjfr(swqillyuno) = rldnkrocbt duuttoatxd (hasaijsvpy ) View more | - | 02 Jul 2022 | |||
Phase 2 | - | zapgsqvfre(bigjjdwndq) = tdkjkxbsjf qncktiqkiz (xpvqborrjz ) View more | Negative | 15 Aug 2020 | |||
Not Applicable | Arthritis IL-6 | IL-17A | - | PD-1 inhibitor monotherapy | kkcrhwwjcf(ajoogudder) = Four patients developed arthritis after PD-1 inhibitor monotherapy and three after combination therapy with CTLA-4 and PD-1 inhibitors. Two patients in the combination therapy group required interleukin (IL)-6 receptor inhibitor therapy in addition to steroids, compared with one patient in the monotherapy group (sulfasalazine). msodcxfxks (xoojfmkhab ) | Positive | 12 Nov 2019 | |
Combination therapy with CTLA-4 and PD-1 inhibitors | |||||||
Not Applicable | 64 | aPD1 + aCTLA4 | lckogbpwij(bcerpnglxf) = One death from irAEs occurred related to Toxic Epidermal Necrolysis (TEN) cawvfbuuvi (gmhqnfqqkf ) View more | Positive | 30 May 2017 |